<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03176810</url>
  </required_header>
  <id_info>
    <org_study_id>1856</org_study_id>
    <nct_id>NCT03176810</nct_id>
  </id_info>
  <brief_title>Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention</brief_title>
  <acronym>COCOA</acronym>
  <official_title>Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takashi Kubo, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to demonstrate the superiority of optical coherence tomography&#xD;
      (OCT)-guided percutaneous coronary intervention (PCI) compared with Angiography-guided PCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison between Optimal Coherence tomography guidance and Angiography Guidance in&#xD;
      percutaneous coronary intervention (COCOA) is a prospective, multicentre, randomised,&#xD;
      open-label, parallel group, active-controlled, superiority trial comparing minimum stent area&#xD;
      immediately after optical coherence tomography (OCT)-guided percutaneous coronary&#xD;
      intervention (PCI) with those after Angiography-guided PCI with a second generation&#xD;
      drug-eluting stent.The primary endpoint of the present study was minimum stent area&#xD;
      immediately after PCI. The secondary endpoint was target vessel failure (defined as a&#xD;
      composite of cardiac death, target-vessel related myocardial infarction, and ischaemia-driven&#xD;
      target vessel revascularisation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimum stent area</measure>
    <time_frame>Immediately after PCI</time_frame>
    <description>Minimum stent area is measured by OCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>12-month afte PCI</time_frame>
    <description>Target vessel failure is defined as a composite of cardiac death, target-vessel related myocardial infarction, and ischaemia-driven target vessel revascularisation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>OCT-guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI is performed by OCT guidance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCI is performed by angiography guidance alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCT</intervention_name>
    <description>OCT is used to guide PCI.</description>
    <arm_group_label>OCT-guided PCI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angiography</intervention_name>
    <description>Angiography is used to guide PCI.</description>
    <arm_group_label>Angiography-guided PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients eligible for PCI using drug-eluting stent (DES) to a de novo native coronary&#xD;
             artery lesion in stable angina pectoris, unstable angina pectoris or non-ST-segment&#xD;
             elevation myocardial infarction (evaluated based on the guideline)&#xD;
&#xD;
          2. Aged 20 years or older at the time of their consent&#xD;
&#xD;
          3. Patients who agree to be enrolled in the trial giving signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Patients who have showed ST-segment elevation myocardial infarction in previous 3 months&#xD;
        2) Patients with cardiogenic shock 3) Patients with heart failure 4) Patients with 3-vessel&#xD;
        disease 5) Patients scheduled to use bare metal stent 6) Patients with renal function&#xD;
        disorder (eGFR 30 mL/min/1.73 m2 or less or serum creatinine 1.5 mg/dL or more) 7) Patients&#xD;
        undergoing hemodialysis 8) Patients with allergies to aspirin, clopidogrel, prasugrel,&#xD;
        heparin, and iodinated contrast agents 9) Patients with hemorrhagic complications such as&#xD;
        intracranial hemorrhage and gastrointestinal bleeding 10) Patients scheduled to undergo&#xD;
        surgical treatment after PCI within 1 year 11) Patients participating in the clinical study&#xD;
        of other medical device or drug and who were considered affecting the primary endpoint of&#xD;
        this study by the physician in charge 12) Patients with one or more co-morbidities that&#xD;
        shorten life expectancy to less than 12 months or that may interfere with the study process&#xD;
        according to this study protocol 13) Patients scheduled to use IVUS in PCI 14) Patients in&#xD;
        whom the form of the target disease concerned is applicable to any of the following&#xD;
        lesions: (i) Lesion in the previously (within 1 year) treated coronary artery or lesion in&#xD;
        the coronary artery with the other lesions requiring revascularization with PCI in the near&#xD;
        future (within 1 year) (ii) Lesion in the left main coronary artery (iii) Lesion in the&#xD;
        coronary bypass graft (iv) Aorto-ostial lesion in right coronary artery (arising within 3&#xD;
        mm of the origin of a right coronary artery) (v) Lesion of chronic total occlusion (vi)&#xD;
        Coronary bifurcation lesion requiring revascularization with 2 stents (vii) Coronary bypass&#xD;
        graft lesion (viii) Lesion in coronary artery with diameter of &lt; 2.5mm or &gt;4.00mm (ix) Long&#xD;
        lesion (length &gt;40mm) (x) Lesion in coronary artery where we expected difficulty in&#xD;
        advancing the OCT catheter (e.g. extremely tortuous artery or severely calcified artery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi Akaska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wakayama Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>6418509</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2017</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Wakayama Medical University</investigator_affiliation>
    <investigator_full_name>Takashi Kubo, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

